Hi-Tech Pharmacal Co, Inc. (HITK) – StreetInsider.com Reports
-
Actavis (ACT) to Acquire Products from Akorn (AKRX)
-
Pre-Open Stock Movers 4/16: (ZLCS) (SODA) (YHOO) Higher; (ASML) (CSX) (TWTR) Lower (more...)
-
After-Hours Stock Movers 4/15: (YHOO) (BIDU) (INTC) Higher; (ATHL) Lower (more...)
-
Repligen Corporation (RGEN) Set to Join the S&P SmallCap 600
-
Akorn, Inc. (AKRX) Receives FTC Approval to Acquire Hi-Tech Pharmacal (HITK)
-
GAMCO Raises Stake in Hi-Tech Pharmacal Co, Inc. (HITK) to 5.61%
-
Hi-Tech Pharmacal Co. (HITK) Tops Q3 EPS by 9c
-
Hi-Tech Pharmacal (HITK) Receives Final Approval for Generic Bromday
-
Hi-Tech Pharmacal (HITK) Investigation in Texas Closes; Will Pay $25M Fine
-
Hi-Tech Pharmacal Co. (HITK) Tops Q2 EPS by 23c
-
Trading Radar for 12/10: AutoZone (AZO), Smith & Wesson (SWHC), H&R Block (HRB), NCI Building Systems (NCS) Report
-
Hi-Tech Pharmacal Co. (HITK) Reports In-Line Q1 EPS
-
Trading Radar for 09/09: PVH Corp. (PVH), Palo Alto (PANW), Hovnanian (HOV), Five Below (FIVE) Report
-
Akorn (AKRX) PT Lifted to $22 at Needham & Company after Hi-Tech Takeover
-
Unusual 11 Mid-Day Movers 08/27: (CPRX) (HITK) (GGS) Higher; (FFHL) (ACUR) (URZ) Lower
-
Want a Quick 3% Pop In Your Stock? Make an Acqusition
-
Notable Mergers and Acquisitions of the Day 08/27: (AKRX)/(HITK) (AZN) (SAM)
-
Standpoint Research Downgrades Hi Tech Pharmacal (HITK) to Hold
-
Pre-Open Stock Movers 8/27: (CPRX) (HITK) (MOV) Higher; (FFHL) (ACUR) (LDK) Lower (more...)
-
CRT Capital Downgrades Hi Tech Pharmacal (HITK) to Fairly Valued
-
Akorn (AKRX) to Acquire Hi-Tech (HITK) in $640M Deal
-
Hi-Tech Pharmacal (HITK) halted with news pending
-
Needham & Company Cuts Numbers on Hi Tech Pharmacal (HITK) After Latest Miss
-
Hi-Tech Pharmacal Co. (HITK) Misses Q4 EPS by 13c, Sales Light
-
Trading Radar for 07/09: Magnum Hunter (MHR), Helen Of Troy (HELE), Wolverine World Wide (WWW) Report
-
Standpoint Research Upgrades Hi Tech Pharmacal (HITK) to Buy
-
Hi-Tech Pharmacal Co. (HITK) Misses Q3 EPS by 28c
-
FMR LLC Raises Stake in Hi-Tech Pharmacal Co, Inc. (HITK) to 12.49%
-
Q2 Results Remove Uncertainty in Hi Tech Pharmacal (HITK)
-
Unusual 11 Mid-Day Movers 12/06: (BSDM) (EPHC) (MBLX) Higher; (TIGR) (LFVN) (NBY) Lower
-
Hi-Tech Pharmacal Co. (HITK) Tops Q2 EPS by 7c
-
Trading Radar for 12/06: lululemon athletica (LULU), Smithfield Foods (SFD), H&R Block (HRB), Palo Alto Networks (PANW) Report
-
Standpoint Research Downgrades Hi Tech Pharmacal (HITK) to Hold
-
Hi-Tech Pharmacal Co, Inc. (HITK) Declares $1.50 Special Dividend; 4.8% Yield
-
Unusual 11 Mid-Day Movers 11/29: (HGSH) (ACUR) (BLOX) Higher; (LQDT) (VRML) (LZB) Lower
-
Hi-Tech Pharmacal (HITK) Could See Pressure on Negative Article
-
Unusual 11 Mid-Day Movers 09/05: (BONT) (CCRN) (PSTI) Higher; (AUQ) (VRS) (FRAN) Lower
-
Hi-Tech Pharmacal Co. (HITK) Misses Q1 EPS by 24c; Sales Light
-
Hi Tech Pharmacal Co. Inc. (HITK) halted, news pending
-
Canaccord Genuity Reiterates a 'Buy' on Hi Tech Pharmacal (HITK); Highlights From Meeting with CEO/CFO
-
CRT Capital Upgrades Hi Tech Pharmacal (HITK) to Buy
-
Needham & Company on Hi Tech Pharmacal (HITK): Four Reason to Buy the Stock Here
-
Needham & Company Maintains a 'Hold' on Hi Tech Pharmacal (HITK); Q4 Mixed; Flonase Beginning To Show Its Age
-
Hi-Tech Pharmacal Co. (HITK) Misses Q4 EPS by 5c
-
Trading Radar for 07/10: Wolverine World Wide (WWW), Shaw Group (SHAW), OCZ Tech (OCZ), VOXX Int'l (VOZZ) Report
-
Canaccord Genuity Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Accumulate on Pullback
-
Canaccord Genuity Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Bumpy Q4 Could Double As Inflection Point
-
Standpoint Research Starts Hi Tech Pharmacal (HITK) at Buy; Large Pipeline
-
Canaccord Genuity Maintains a 'Buy' on Hi Tech Pharmacal (HITK); Updating Model
-
Needham & Company Maintains a 'Hold' on Hi Tech Pharmacal (HITK); Upside Momentum Stalls Out In 3Q
Back to HITK Stock Lookup